WebMay 21, 2008 · The TSC1 and TSC2 proteins form a relatively tight stoichiometric complex in cells, which functions in an ancestrally conserved signaling pathway that regulates the state of activation of mammalian target of rapamycin (mTOR) and thereby cell growth ( Goncharova et al., 2002; Kwiatkowski et al., 2002; Inoki et al., 2005; Tee and Blenis, … WebJan 20, 2024 · Tuberous sclerosis complex (TSC), also known as tuberous sclerosis, is a rare genetic disease that causes non-cancerous (benign) tumors to grow in the brain and several areas of the body, including the spinal cord, nerves, eyes, lung, heart, kidneys, …
TSC1 Loss - My Cancer Genome
WebOct 14, 2012 · Major finding: TSC1 -mutant bladder cancers had better responses to everolimus than TSC1 –wild-type tumors. Clinical relevance: Sequencing the tumor genomes of outlier patients may uncover the basis of their drug response. Impact: mTOR-targeted therapies may be especially effective in patients with somatic TSC1 mutations. WebAug 15, 2024 · Rapamycin is FDA-approved for the treatment of transplant and cancer patients. The drug is also referred to as sirolimus and is sold under the name Rapamune. Publicly available data suggest that the drug might also … du tap the
Loss of Tsc1 in cerebellar Purkinje cells induces ... - eLife
WebApr 14, 2024 · Merck is readily evaluating its flagship product as a combination in high-grade serous ovarian carcinoma, Aadi Biosciences heading towards grabbing a tumor agnostic label in TSC1 or TSC2 mutation. WebApr 15, 2024 · Tuberous sclerosis complex (TSC) is a rare genetic multisystem disorder caused by loss-of-function mutations in the tumour suppressors TSC1/TSC2, both of which are negative regulators of the mammalian target of rapamycin (mTOR) kinase. Importantly, mTOR hyperactivity seems to be linked with the pathobiology of autism spectrum … WebNov 12, 2024 · TSC1/2-mutated PEComas sometimes respond to mTOR-inhibition therapy , but these drugs are mechanistically believed to be inefficient in TFE3-altered PEComa. MET-inhibitors, on the other hand, are active in alveolar soft part sarcoma with TFE3 rearrangement [ 20 ], a rare subtype of soft-tissue sarcoma, and could constitute a … duval high school lio rush